Selective estrogen receptor modulation: A personal perspective

Cancer Research

Volumn 61, Issue 15, 2001, Pages 5683-5687

  Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ANIMALS; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0035421182     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Fashions in cancer research
2. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
3. Approaches to prevention of epithelial cancer during the preneoplastic period
4. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture
5. Designer estrogens
6. Basic guides to the mechanism of estrogen action
7. Hormone receptors: Studies on the interaction of estrogen with the uterus
8. Estrogen receptors and breast cancer response to adrenalectomy
9. A non-steroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenylethanol
10. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats
11. The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole
12. Tamoxifen: A personal retrospective
13. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474
14. Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels
15. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer
16. Tamoxifen (ICI 46,474), and the human carcinoma 8S oestrogen receptor
17. Tamoxifen as an antitumour agent: Oestrogen binding as a predictive test for tumour response
18. Tamoxifen (antiestrogen) therapy in advanced breast cancer
19. The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer
20. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy
21. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice
22. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
23. EBCTCG tamoxifen for early breast cancer: An overview of the randomized trials
24. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years
25. Effect of tamoxifen (ICI 46.474) on initiation and growth of DMBA-induced rat mammary carcinomata
26. Pharmacology of tamoxifen in laboratory animals
27. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
28. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
29. Species-specific pharmacology of antiestrogens: Role of metabolism
30. Effects of anti-estrogens on bone in castrated and intact female rats
31. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats
32. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats
33. Effects of tamoxifen on spinal bone density in women with breast cancer
34. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
35. Antagonism of estrogen action with a new benzothiophene derived antiestrogen
36. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model
37. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice
38. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
39. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
40. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation
41. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60
42. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women
43. Tamoxifen, raloxifene, and the prevention of breast cancer
44. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
45. Cloning of a novel receptor expressed in rat prostate and ovary
46. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
47. Comparative analyses of mechanistic differences among antiestrogens
48. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription
49. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites
50. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain
51. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog
52. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor
53. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor α mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
54. Molecular basis of agonism and antagonism in the oestrogen receptor
55. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
56. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist
57. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor
58. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
59. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351
60. Molecular mechanism of action at estrogen receptor α of a new clinically relevant antiestrogen (GW7604) related to tamoxifen
61. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: A non-steroidal estrogen with functional selectivity for bone over uterus in rats
62. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor
63. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex
64. Structural insights into the mode of action of a pure antiestrogen
65. Regulation of prolactin synthesis in vitro by estrogenic and antiestrogenic derivatives of estradiol and estrone
66. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
67. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
68. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
69. LY353381. HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo
70. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models
71. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
72. Antiandrogens in prostate cancer
73. Selective androgen receptor modulators (SARMS): A novel approach to androgen therapy for the new millennium
74. Development of selective aryl hydrocarbon receptor modulators (SAhRMs) for treatment of breast cancer
75. Prospects for the prevention and treatment of cancer with SPARMs (selective PPARγ modulators)
76. A sweetheart deal for the thyroid hormone